Absci Corp ABSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
-
As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models
-
The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
-
Healthcare stocks have become a haven for investors ditching tech
-
Absci Reports Data From Trial for Hair-Loss Treatment, Prices $100 Million Stock Offering
-
The Quiet Bottleneck in AI Drug Discovery Isn't the Model — It's the Biology Underneath It
-
Absci Shares Fall on Wider 4Q Loss, Lower Revenue
Trading Information
- Previous Close Price
- $8.16
- Day Range
- $7.85–8.40
- 52-Week Range
- $2.24–12.06
- Bid/Ask
- $8.24 / $8.50
- Shares Outstanding
- 169.40M
- Market Cap
- $1.41B
- Volume/Avg
- 3M / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 650.13
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 140
- Website
- https://www.absci.com
Valuation
|
Metric
|
ABSI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.49 |
Price/Sales | 650.13 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ABSI
|
|---|---|
Quick Ratio | 6.28 |
Current Ratio | 6.59 |
Interest Coverage | −798.63 |
Quick Ratio
ABSI
Profitability
|
Metric
|
ABSI
|
|---|---|
Return on Assets (Normalized) | −49.31% |
Return on Equity (Normalized) | −57.43% |
Return on Invested Capital (Normalized) | −55.47% |
Return on Assets
ABSI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|H$@v@b | LOCK|wnJcl | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|BZcPql | LOCK|$D&qF | $71B | |||
| argenx SE ADR
ARGX
| LOCK|ncVg@# | LOCK|!< | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|YkGvZ> | LOCK|^c% | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|C^KJzY | LOCK|xNgvQ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|dSQ@PjVm | LOCK|l!XK | $26B | |||
| Moderna Inc
MRNA
| LOCK|#%SfXl | LOCK|B< | $24B | |||
| Incyte Corp
INCY
| LOCK|^k#@$zS | LOCK|sV | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Z?#^XM | LOCK|&y | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|@>?kmN% | LOCK|>! | $16B |
United States